Follow-Up Care After Completing Therapy for HER2-Positive Invasive Ductal Carcinoma

Rationale for Treatment Discontinuation

For a patient 12 years after diagnosis who has completed 10 years of adjuvant therapy with no evidence of disease, active treatment should be discontinued and the patient should transition to standard surveillance without ongoing HER2-targeted therapy, as recommended by the American College of Physicians and supported by the American Society of Clinical Oncology 1, 2, 3, 4, 5
Treatment continuation beyond 10 years is not supported by evidence, with the standard duration of adjuvant trastuzumab-based therapy being 52 weeks, according to the National Comprehensive Cancer Network 6
For patients with prolonged complete response, treatment discontinuation can be considered on a case-by-case basis, with retrospective data showing excellent outcomes, including 5-year overall survival of 90.5% and 10-year overall survival of 87%, as reported by the American Cancer Society 1, 2, 3, 4, 5

Standard breast cancer surveillance should continue indefinitely, with clinical examination every 3-6 months for the first 3 years after completing treatment, then every 6-12 months for years 4-5, then annually, as recommended by the American College of Radiology 6
Annual mammography and breast MRI if indicated based on breast density or genetic risk factors should be performed, according to the Society of Breast Imaging 6
No routine laboratory testing or imaging beyond mammography is recommended in asymptomatic patients without evidence of recurrence, as stated by the American Society of Clinical Oncology 6

If recurrence occurs >12 months after completing adjuvant treatment, restart first-line HER2-targeted therapy with trastuzumab, pertuzumab, and taxane-based chemotherapy, as recommended by the National Comprehensive Cancer Network 7, 6
At 12 years post-diagnosis, any recurrence would be considered late recurrence and should be treated as first-line metastatic disease, according to the American Cancer Society 7, 6

If the patient's tumor was hormone receptor-positive, endocrine therapy should continue for at least 5-10 years total from diagnosis, as recommended by the American Society of Clinical Oncology 6
Endocrine therapy continuation is independent of HER2-targeted therapy completion, according to the National Comprehensive Cancer Network 6